




The entire panel participated in the responses to most
questions; the summary represents a concensus.
Prof. Saling opened the discussion with two important
questions (1) when and whom to screen for hypoglycemia and (2)
what is explanation of LGA neonate in the absence of glucose
abnormal ities or hyperinsulinism.
All agreed that all high risk infants be screened frequently,
beginning at or shortly after birth. To the high risk group Prof.
Saling added the infant with 2 hours or more tachycardia prior to
delivery.
To explain increased birth weight, the following were
vproposed (1) HbAjc to detect unrecognized gestational diabetics
(2) note carefuliy any disproportionate organ growth e.g. small
brain and kidney in the presence of excess fat, heavy placenta,
liver and heart suggests hyperinsulinism. (3) Maternal diet and
its composition e.g. 12,600 births compared between Palermo and
Gotteborg, Prof. Karlberg found in Italy, gestation was 5 days
shorter, infants 10 cm. shorter and 100 gms heavier than in
Sweden. Is this related to high carbohydrate (Pasta) diet? (4)
Sould pregnant women nibble rather than eat l or 2 or 3 meals/day?
Another major area discussed - at what level of blood glucose
does brain damage occur? Is this related to rate of fall of
glucose or to age of infant (hours vs days after birth)? There
are no definitive answers without precise measures of neonatal
brain function. Suggestions for study included the infants
activity, the presence of a normal evoked potential on EEG and
long term follow-up. All agreed that the new techniques to
measure brain glucose metabolism äs well äs blood flow on an
ongoing basis äs is available with Positron Emitting Tomography
(P.E.T.) wil l be necessary to answer this question.
All agreed that early feeding (breast, formula) and support
of the blood glucose is important if we are to prevent whatever
damage hypoglycemia may induce.
A discussion of the safety and use of intralipid indicated
that while most teaching centers in Sweden use intralipid, all
appear satisfied that it stimulates gluconeogenesis and provides
needed calories and energy for the SGA infants. Potential dangers
include increased oxygen consumption and its effect on cardiac
Output. In therapy, intralipid (2 gm/day) is used äs an adjunct
to ongoing intravenous glucose therapy.
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